Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Satralizumab Accepted for Review in Europe, US; Chugai Plans Japan Filing Before Year-End
Chugai Pharmaceutical said on October 30 that European and US regulators have accepted marketing applications for satralizumab (development code: SA237), an anti-IL-6 receptor humanized recycling antibody, for adult and adolescent patients with neuromyelitis optica spectrum disorder (NMOSD). The Medicines Agency…
To read the full story
Related Article
- Chugai’s Satralizumab Hits Primary Target in PIII Study
September 13, 2019
- Chugai’s Satralizumab Wins FDA Breakthrough Therapy Status
December 20, 2018
BUSINESS
- FDA Extends Review of Capricor’s DMD Cell Therapy by 3 Months
August 26, 2026
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…